Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIOW)
| Market Cap | 2.63M-49.8% |
| Revenue (ttm) | 14.45K-25.9% |
| Net Income | -6.47M-3.5% |
| EPS | -2.92-41.6% |
| Shares Out | 2.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,778 |
| Open | 0.01 |
| Previous Close | 0.02 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.02 |
| Beta | 2.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 2, 2026 |
About CDIOW
Founded in Chicago, Illinois, in 2017, Cardio Diagnostics Holdings, Inc. specializes in the creation and market introduction of clinical tests. These diagnostic tools leverage epigenetics to assess cardiovascular disease risk. Among its offerings is Epi+Gen CHD, a test designed to predict the risk of symptomatic coronary heart disease over a three-year timeframe.
$CDIOW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CDIOW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CDIOW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CDIOW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CDIOW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CDIOW from public contracts
Source: USAspending.gov
CDIOW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CDIOW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.